Regulatory Approvals
Government authorizations required before specific M&A transactions can close. Common categories: antitrust/competition (HSR Act filings for deals above thresholds), financial services (banking regulators for financial institution acquisitions), healthcare (state healthcare authority approvals for hospital, physician practice, or insurance deals), foreign investment (CFIUS review when foreign parties are involved), and professional licensing (state board approvals for licensed business transfers). Missing regulatory approvals is a closing condition failure.
Full Definition
Regulatory approvals are government or agency authorizations that must be obtained before an M&A transaction can legally close. They range from antitrust reviews (Hart-Scott-Rodino filings in the U.S. for deals above the HSR threshold), to industry-specific licenses (banking, insurance, healthcare, telecom), to foreign investment reviews (CFIUS in the U.S., similar bodies in the EU and UK), to state-level change-of-ownership permits. Failure to secure required approvals before closing is not just a technicality — it can render a transaction void and expose both parties to substantial fines.
In SMB transactions (typically $1M–$50M), most deals fall below the HSR filing threshold (currently around $119 million in deal value), so federal antitrust review is rarely required. However, industry-specific approvals are far more common than buyers expect. A healthcare practice acquisition may require state medical board notification, Medicare/Medicaid provider number reassignment, and HIPAA business associate agreements. A regulated financial services firm needs state money transmitter license transfers. A restaurant chain may need local health permits reissued in the buyer's name.
The critical deal-structuring question is whether approvals transfer automatically in an asset sale versus a stock sale. In an asset purchase, most licenses must be re-applied for in the buyer's name, which can take weeks or months. In a stock purchase, licenses often stay with the entity, but change-of-control clauses in contracts with government agencies may still trigger a reapproval requirement.
Regulatory approval timelines must be baked into the deal schedule. Experienced buyers set outside dates that provide sufficient buffer for approval processes — and include MAC (material adverse change) provisions that allow termination if approvals are unreasonably delayed or denied.
Seller vs. Buyer Perspective
Sellers are often surprised by the number of regulatory approvals that apply to their business. Before signing an LOI, audit every license, permit, and government contract you hold and determine which ones carry change-of-control provisions. A license that cannot transfer without a six-month re-application process is a deal risk you need to disclose early — not discover three weeks before closing.
Cooperate fully with the buyer's regulatory counsel. Delayed approval filings due to incomplete seller documentation are a common cause of closing extensions and renegotiated terms. Sellers who drag their feet on government filings lose leverage.
Map every required approval before signing the LOI and build realistic timelines into the purchase agreement. Nothing is worse than a deal that is fully negotiated and financially closed but sitting on a desk at a state licensing board. Use an attorney with specific experience in the target's industry — a generalist M&A lawyer may miss sector-specific requirements.
Where approvals are the critical path item, structure the deal so that the outside date extends automatically if the delay is caused by regulatory processing (not by either party's action). You do not want to be forced to terminate a good deal simply because a state agency took 30 days longer than expected.
Real-World Example
A buyer acquired a home health agency in a stock purchase. The business held a state-issued Medicaid provider number. Despite the stock structure, the state required a change-of-ownership (CHOW) filing that took 90 days to process. The purchase agreement had a 60-day outside date. The parties had to negotiate a closing extension and an interim management agreement allowing the seller to continue operating while the buyer awaited approval.
Why It Matters & Common Pitfalls
- !Assuming stock deals avoid licensing issues. Change-of-control provisions in government contracts, licenses, and regulated programs frequently require notification or reapproval even in stock purchases. Always review every license for change-of-control language.
- !Underestimating agency timelines. State licensing boards are often understaffed. What a buyer assumes will take 30 days can take 90. Build buffer into every outside date and closing timeline.
- !CFIUS blind spots. Foreign buyers often underestimate U.S. national security review exposure, particularly for businesses touching technology, data, or critical infrastructure. CFIUS review can last six months or more and may result in mandatory divestitures or deal prohibition.
- !Medicare/Medicaid billing gaps. In healthcare acquisitions, there is often a billing gap between when the seller's provider number is deactivated and when the buyer's number is activated. Unaddressed, this gap creates weeks of unbillable services — a significant cash flow hit for the buyer.
Frequently Asked Questions
What regulatory approvals are needed in M&A?↓
How long do regulatory approvals take?↓
Related Terms
Hart-Scott-Rodino (HSR) Act
A federal law requiring advance notification to the FTC and DOJ for M&A transactions above certain size thresholds — triggering a mandatory waiting period for antitrust review before closing.
Closing Conditions
Closing conditions are requirements that must be met before a deal can close — regulatory approvals, rep accuracy, no material adverse change. Failure to satisfy can delay or kill deals.
CFIUS Review
The Committee on Foreign Investment in the United States — an interagency body that reviews acquisitions of US businesses by foreign buyers for national security implications. CFIUS can recommend the President block a deal, require divestitures of sensitive assets, or impose operating conditions (mitigation agreements). Filing is mandatory for certain transactions involving foreign government ownership; voluntary for others. Deals in defense, semiconductors, critical infrastructure, sensitive personal data, and advanced technology face the highest scrutiny. Processing time: 30-45 days for standard review, up to 90 days for full investigation.
Change of Control
A change of control occurs when ownership or management control of a company transfers. Many contracts include change of control provisions that can affect M&A deals.
Get Weekly M&A Insights
Valuation data, deal analysis, and plain-English M&A education — every week.
The LegacyVector Newsletter
Join 5,000+ business owners, investors, and buyers who get weekly M&A market data and deal insights.
- Weekly valuation multiples by industry
- SBA lending rates & deal financing data
- Market trends & acquisition opportunities
No spam. Unsubscribe anytime. Free forever.
Disclaimer: The information provided on this page is for educational and informational purposes only. It should not be considered financial, legal, or investment advice. Business valuations depend on many factors specific to each situation. Always consult with qualified professionals — including business brokers, CPAs, and M&A attorneys — before making acquisition or sale decisions. LegacyVector is not a licensed broker, financial advisor, or attorney. Data shown may be based on limited samples and may not reflect current market conditions.
LegacyVector Research Team
Reviewed by M&A professionals · Updated April 2026